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8Rationale & Objective: The efficacy and safety of
icodextrin versus glucose-only peritoneal dialysis
(PD) regimens is unclear. The aim of this study
was to compare once-daily long-dwell icodextrin
versus glucose among patients with kidney
failure undergoing PD.
Study Design: Systematic review of randomized
controlled trials (RCTs), enriched with unpub-
lished data from investigator-initiated and
industry-sponsored studies.
Setting & Study Populations: Individuals with
kidney failure receiving regular PD treatment
enrolled in clinical trials of dialysate composition.
Selection Criteria for Studies: Medline,
Embase, CENTRAL, Ichushi Web, 10 Chinese
databases, clinical trials registries, conference
proceedings, and citation lists from inception to
November 2018. Further data were obtained
from principal investigators and industry clinical
study reports.
Data Extraction: 2 independent reviewers
selected studies and extracted data using a
prespecified extraction instrument.
Analytic Approach: Qualitative synthesis of
demographics, measurement scales, and out-
comes. Quantitative synthesis with Mantel-
Haenszel risk ratios (RRs), Peto odds ratios
(ORs), or (standardized) mean differences
(MDs). Risk of bias of included studies at the
outcome level was assessed using the
Cochrane risk-of-bias tool for RCTs.Editorial, p. 821
30Results: 19 RCTs that enrolled 1,693 partici-
pants were meta-analyzed. Ultrafiltration was
improved with icodextrin (medium-term MD,
208.92 [95% CI, 99.69-318.14] mL/24 h; high
certainty of evidence), reflected also by fewer
episodes of fluid overload (RR, 0.43 [95% CI,
0.24-0.78]; high certainty). Icodextrin-containing
PD probably decreased mortality risk compared
to glucose-only PD (Peto OR, 0.49 [95% CI,
0.24-1.00]; moderate certainty). Despite
evidence of lower peritoneal glucose absorption
with icodextrin-containing PD (medium-term
MD, −40.84 [95% CI, −48.09 to −33.59] g/
long dwell; high certainty), this did not directly
translate to changes in fasting plasma glucose
(−0.50 [95% CI, −1.19 to 0.18] mmol/L; low
certainty) and hemoglobin A1c levels (−0.14%
[95% CI, −0.34% to 0.05%]; high certainty).
Safety outcomes and residual kidney function
were similar in both groups; health-related
quality-of-life and pain scores were inconclusive.
Limitations: Trial quality was variable. The follow-
up period was heterogeneous, with a paucity of
assessments over the long term. Mortality
results are based on just 32 events and were
not corroborated using time-to-event analysis of
individual patient data.
Conclusions: Icodextrin for once-daily long-dwell
PD has clinical benefit for some patients,
including those not meeting ultrafiltration targets
and at risk for fluid overload. Future research into
patient-centered outcomes and cost-
effectiveness associated with icodextrin is needed.The prevalence of kidney replacement therapy is ex-pected to increase steeply.1 Approximately 15% of
dialysis patients globally use peritoneal dialysis (PD), and
this proportion is increasing.2 PD is probably associatedwith the same survival as hemodialysis (HD)3-6 but pre-
sents certain lifestyle benefits (eg, patient satisfaction,7-10
employment,11-15 treatment flexibility,16 and some as-
pects of health-related quality of life [HRQoL]17-21). PD is
not clinically appropriate for everyone,22,23 and many
patients require transfer to HD within their lifetime.24-26The dialysate itself is an acknowledged Achilles heel of
PD. Glucose is not an ideal osmotic agent because it is
easily absorbed, thereby attenuating the osmotic gradient
driving ultrafiltration (UF). This absorption can lead to
hyperinsulinemia, hyperlipidemia, and weight gain.27-29
Furthermore, glucose and its degradation products
(GDPs) contribute to peritoneal fibrosis and vasculopathy
and increased membrane permeability.30-33 The resulting
lower clearance of uremic toxins and volume overload
probably contribute to the increased cardiovascular death
in this population.34-36
Alternative osmotic agents have been a long-standing
consideration.37-39 Icodextrin is a soluble glucoseAJKD Vol 75 | Iss 6 | June 2020
Original Investigationpolymer that was first registered for sale in 1997, and is
used widely (Fig S1). Three systematic reviews of ran-
domized controlled trials (RCTs) have compared
icodextrin-containing to glucose-only PD regimens.40-42
However, their estimates of important outcomes such as
mortality risk and hospitalization, as well as systemic
metabolism and peritoneal function, have wide confidence
intervals (CIs). This uncertainty may have arisen because of
nonincluded evidence, such as unpublished data from
published studies, studies published in non-English lan-
guages, and studies that have undergone regulatory as
opposed to academic peer review.
The aim of this systematic review was to compare once-
daily long-dwell icodextrin versus glucose in RCTs of
patients with kidney failure undergoing PD. Primary out-
comes were patient survival, PD technique survival,
HRQoL, and UF volume. Secondary outcomes related to
safety, kidney function, and laboratory parameters. A
further aim was to incorporate evidence not previously
meta-analyzed, with a view to a more comprehensive and
transparent review. Key sources for obtaining additional
data were manufacturers’ clinical study reports (CSRs).
These contain more complete clinical trial information,43
and their inclusion in systematic reviews has been shown
to reduce reporting biases,44 particularly of harms out-
comes.45 Following calls for the release46,47 and greater
use of regulatory documents in systematic reviews,48 this
is the first case of industry volunteering these data for
meta-analysis, as far as we are aware.Methods
Study Reporting and Registration
This systematic review and meta-analysis is reported
according to the Preferred Reporting Items for Systematic
Reviews and Meta-analyses (PRISMA) guidelines.49
The protocol was registered with PROSPERO
(CRD42018096951)50 and published prospectively.51
Eligibility Criteria and Outcomes
The population was adults and children with kidney failure
receiving any type of PD. The intervention was long-dwell
icodextrin used as a single osmotic agent, and the com-
parison was long-dwell glucose (any concentration) used
as a single osmotic agent. Primary outcomes were patient
survival (number of deaths during treatment), PD tech-
nique survival (number of conversions to HD), HRQoL
(36-Item Short Form Health Survey [SF-36] generic
questionnaire physical and mental component summaries;
disease-specific modules’ overall score), and peritoneal UF
(net long-dwell UF in mL, total 24-hour UF in mL).
Secondary outcomes were safety (serious and total adverse
events [AEs] and AEs leading to withdrawal, hospitaliza-
tions, peritonitis, and uncontrolled fluid overload); kidney
function (residual urine volume in mL/d; any other
measure including weekly renal Kt/Vurea or residual
glomerular filtration rate); drained body weight (in kg);AJKD Vol 75 | Iss 6 | June 2020peritoneal creatinine and urea clearances (any measure);
peritoneal glucose exposure (in g/24 h) and absorption
(in g/long dwell); glycated hemoglobin {HbA1c; %) level;
plasma/serum concentrations of glucose, sodium, total
cholesterol, and triglycerides (each in mmol/L); and
inflow pain (number of events). Eligible study designs
were (quasi-)RCTs (published and unpublished). There
were no language or date restrictions.
Literature Search
The following databases were systematically searched from
inception to November 2018: Medline (via PubMed),
Embase, CENTRAL, Ichushi Web, and Chinese databases
(China National Knowledge Infrastructure,52 Chongqing,53
Wanfang Data,54 HK government library,55 Hyread,56 Eric-
data,57 National Digital Library of Theses and Dissertations in
Taiwan,4 Taiwan Journal Papers Index System,5 TAO Taiwan
Academic Online,6 and Ariti Library7). Clinical trials regis-
tries were searched to identify ongoing and recently
completed studies (ClinicalTrials.gov, International Clinical
Trials Registry Platform, EU Clinical Trials Register, Japan
registries network, and China’s Clinical Trial Registry;
Table S1). The search strategywas developed in collaboration
with an experienced librarian and checked according to the
Peer Review of Electronic Search Strategies guideline.58
Table S2 provides details for all searches.
Between June and September 2018, all available con-
ference proceedings of the American Society of
Nephrology and International Society for Peritoneal Dial-
ysis were screened. The reference lists of all included
primary studies and relevant systematic reviews were
manually cross-checked for additional studies. The relevant
manufacturers (Baxter Healthcare9 and Terumo10) were
contacted to identify further studies and provide CSRs. In
addition, principal investigators and other experts were
contacted for additional references or data.
Study Selection
Two reviewers independently screened the titles and ab-
stracts retrieved through Medline, Embase, and CENTRAL
and assessed full texts of all potentially relevant articles
against predefined selection criteria. Titles and abstracts
identified in Ichushi-Web and Chinese databases were
screened by 1 reviewer. Subsequently, abstracts and full
texts of potentially relevant articles were assessed by 2
further reviewers. Disagreements were resolved through
consensus or by consulting a third reviewer. Correspond-
ing authors of eligible articles were contacted for clarifi-
cation when necessary. Clinical trials registries were
searched by 1 reviewer, and potentially relevant trials then
were assessed by a further reviewer. Reasons for full-text
exclusion were recorded (Table S3).
Data Extraction
Two reviewers independently extracted data using a stan-
dardized data extraction sheet. A predefined data set was
collected for each trial, consisting of study characteristics831
Original Investigation(country, number of centers, study duration, patient
population, selection criteria, intervention and control
group treatments, number of patients randomly assigned
and analyzed, and funding source), patients’ baseline
characteristics (age, sex, body mass index, cause of kidney
failure, peritoneal membrane transport characteristics by
peritoneal equilibration testing, and residual glomerular
filtration rate), and outcomes data for any time point re-
ported. If a study generated multiple publications or un-
published reports, data were extracted from the most
comprehensive and the others were used to complete this
information. All authors were contacted for further data
and clarification of discrepancies.
Assessment of Risk of Bias and Certainty of
Evidence
Two reviewers independently assessed risk of bias of
included studies at outcome level using the Cochrane risk-
of-bias tool for RCTs.59 The overall risk of bias for any
study was considered high if any of the domains were
judged to be at high risk of bias.
The reviewers independently assessed the certainty of ev-
idence using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) system, considering
risk of bias, inconsistency, indirectness, imprecision, and
other considerations (strength of the association and dose-
response effects).60-71 As is recommended by GRADE and
the Cochrane Collaboration, assessment of the certainty of
evidence was as high, moderate, low, or very low according
to whether the results provided a very good, good, some, or
unreliable indication of the likely effect, respectively. Stan-
dardized wording was used to report the estimated effects,
based on the certainty of evidence in conjunction with the
importance of the effect, also according to Cochrane Collab-
oration recommendations.72
Any disagreements were resolved through consensus or
by consultation with a third reviewer.
Data Analysis/Statistics
For meta-analysis, trial results were grouped into short- (up
to 6 weeks), medium- (3-6 months), and long-term
treatment duration (1-2 years). No study had a duration
between 6 weeks and 3 months or between 6 and 12
months. For studies reporting outcomes at multiple points
in time, results were used for all available subgroups, each
with the longest possible duration. Values reported as mg/
dL were converted to mmol/L using molar weights. Mean
and standard deviation (SD) values were estimated from
median and interquartile range values using the method of
Wan et al73 and from 95% CIs using the methods recom-
mended in the Cochrane Handbook.74 In case no measure
of variability was reported, SDs were imputed using the
mean SD of all other studies in the same subgroup.75,76
Intention-to-treat analyses were used when reported.
When continuous data were available for only a fraction of
the total population, an available-case analysis was832performed when possible to avoid inflating the precision of
the effect estimate.77 Data were meta-analyzed using Rev-
Man, version 5.3 (Nordic Cochrane Centre, Cochrane
Collaboration). Fixed-effect models were used for outcomes
in the absence of heterogeneity (I2 = 0), with sensitivity
analyses using random-effects models. Otherwise, random-
effects models were used. Dichotomous outcomes were
analyzed using Mantel-Haenszel risk ratios (RRs) or, when
event rates were low, Peto odds ratios (ORs). Continuous
outcomes were pooled using the inverse-variance mean
difference (MD) or the standardized MD. Absolute measures
(risk difference or MD) were computed using GRADEpro
GDT.18,58 Point estimates were reported along with 95%
CIs. Heterogeneity between trials was quantified using I2
statistics.78 For each outcome with 10 or more contributing
studies, possible publication bias was evaluated by visual
inspection of funnel plots for asymmetry (Fig S2) and by
Egger test using Meta-Essentials, version 1.4.79 For Egger
test, the null hypothesis was that the funnel plot is sym-
metrical (measured by the intercept from regression of
standard normal deviates against precision), with the alter-
native indicating the presence of funnel plot asymmetry.
Data were entered by 1 reviewer and checked for accuracy
and completeness by a second reviewer.
Forest plots for all outcomes that were meta-analyzed
and further information on planned subgroup analyses
(performed when data were available) and differences be-
tween protocol and review are provided in Figures S3-S7.80Results
Search Results
The search of literature databases identified 895 articles.
Additional records were obtained from trial registries
(Table S2), Baxter Healthcare, and trial authors. Queries to
Terumo did not provide any additional RCTs, nor did the
manual search of conference abstracts. Thirty-nine docu-
ments (23 publications,54,81-102 10 CSRs,103-112 and 6 data
tables) related to 20 RCTs met inclusion criteria (Fig 1).
Seventeen full-text articles were excluded (Table S3).
Trial and Patient Characteristics
Table 1 presents clinical characteristics of included trials.
All were RCTs, 3 with crossover design.81,98,102 Eligible
patients were incident and prevalent adults receiving
continuous ambulatory PD or automated PD, including
diabetic,93,99 nondiabetic,81,86,88 or mixed patient collec-
tives. Three studies85,87,93 were limited to high/high-
average transporters. The differential effects with these
subpopulations were explored by subgroup analyses (Figs
S4-S7).
Most trials explicitly excluded patients with acute
peritonitis, but one focused specifically on such patients.84
One study included solely patients with hypertension
related to volume overload.85 Baseline patient character-
istics are detailed in Table S4.AJKD Vol 75 | Iss 6 | June 2020
Original InvestigationRisk-of-Bias Assessment for Included Trials
The risk of bias of included studies is shown in Figure 2
(details in Table S5). Two studies were judged to be of
high risk of bias overall81,98 because of potential selective
reporting, one of which was also of high risk of attrition
bias.98 For the remaining 18 RCTs, the overall risk of bias
was low/unclear.
Grading of Recommendations
Table S6 provides the GRADE assessment by individual
domains.60 The certainty of evidence was high or mod-
erate for 43 outcomes and low or very low for 12 out-
comes. Table 2 shows GRADE assessment and summary of
findings for selected outcomes.
Publication Bias
Visual inspection of the funnel plots showed no evidence
of publication bias. Egger test did not reach statistical
significance for 12 of 13 outcomes (Fig S2).
Patient Survival
Patient survival was reported by 19 RCTs (1,685 patients).
Icodextrin-containing PD probably decreased mortality
risk compared to glucose-only PD (Peto OR, 0.49 [95% CI,
0.24-1.00]; Figures 3 and S3A; for causes of death see
Tables S7 and S8),113 with moderate heterogeneity
(I2 = 41%). The direction of this effect was consistent in
the mid- and long-term subgroups, reflecting a cumulative
dose effect. Only a single death occurred in all short-termRecords identified through DB
MEDLINE = 168 Embase
CENTRAL = 269 Ishuchi W
China databases = 432
Additional records identified 
via other sources:
conference abstracts = 0
trial registries = 6
pharma company  = 10
author contact = 6
Records after duplicates (n=2
removed: n = 368
Full-text articles assessed for
n = 61
Studies included in quantitati
(meta-analysis):
n = 38 documents related to 19 
Studies included in qualitative
n = 39 documents related to 20 
Figure 1. Flow diagram shows the systematic literature search an
trial.
AJKD Vol 75 | Iss 6 | June 2020studies (641 participants). Heterogeneity may be: (1)
clinical, with variable morbidity of populations (see
Table S4), and (2) statistical, associated with the low event
rate of 1.9%. Subgroup analyses for incident versus prev-
alent patients and diabetic versus nondiabetic patients (Figs
S4A and S5A) showed the same trend.
The absolute control-group risk of death was 25 per
1,000 treated patients. In the icodextrin group, the risk
difference was 13 fewer deaths per 1,000 (0-19 fewer).
Our confidence in this result is moderate because
despite low event rates, heterogeneity, and wide CIs, a
positive effect emerges with long-term treatment and
overall.
PD Technique Survival
PD technique survival was not defined consistently
throughout studies, so we analyzed the number of con-
versions to HD. Pooled event rates for 18 contributing
RCTs (1,401 participants) were low (2.6%). There was no
difference between icodextrin and glucose overall (Peto
OR, 0.77 [95% CI, 0.39-1.50]; moderate certainty) or for
any subgroups (<6 weeks, 1.06 [95% CI, 0.07-17.03]; 3-6
months, 0.59 [95% CI, 0.23, 1.54]; 1-2 years, 0.98 [95%
CI, 0.36-2.68]; incident patients [Fig S4B], 1.29 [95% CI,
0.28-6.03], prevalent patients, 0.81 [95% CI, 0.35-1.84];
diabetic patients [Fig S5B], 1.97 [95% CI, 0.50-7.69]; or
nondiabetic patients [Fig S5B], 0.98 [95% CI, 0.27-3.60]).
The absolute control-group rate of conversion to HD was
29 per 1,000 patients. The overall certainty of the evidence22 full-text articles excluded, reasons:
n = 5 clinical trials (1 ongoing, 2 terminated, 2 
unclear status)
n = 1 study protocol 
n = 1 meeting abstract, publication included 
n = 2 no RCT
n = 2 wrong intervention
n = 11 secondary analysis of included study
295 irrelevant records excluded based on 
title/abstract
 searching:
= 14
eb = 12
32) 
 eligibility:
ve synthesis 
studies
 synthesis:
studies
1 study excluded from meta-analysis
reason: cross-over RCT for which no data 
could be extracted for the first study phase
d selection of articles. Abbreviation: RCT, randomized controlled
833
Table 1. Clinical Characteristics of Included Studies
Study
Design, Duration,
Funding Setting; N Patient Population
Key Exclusion
Criteria Intervention Control
Bredie81 (2001) Crossover RCT,
6 + 6 wk,
public + Baxter
1 center in NL;
22
Prevalent CAPD Peritonitis, DM Noct 1× ico + day 2-3× ≥1.36%
glu (Dianeal)
Noct 1× ≥1.36% glu + day 2-
3× ≥1.36% glu (Dianeal)
Chang82 (2016) Open-label RCT,
12 mo, Baxter
8 centers in KR;
49 ico, 51 glu
Incident + prevalent
CAPD; urine ≥ 750 mL/d
<12-mo life
expectancy; prior ico,
APD, HD; volume
overload
Noct 1× ico + day 2× 1.36%
glu (Physioneal)
1× ≥2.27% + 2× 1.36% glu per 24 h
(Physioneal)
Chen83 (2018) Open-label RCT,
2 y, Baxter
1 center in TW;
21 ico, 22 glu
Adults; incident APD <12-mo life
expectancy, serious
disease
Day 1× ico + noct ≥1.36% glu
(Dianeal) via auto cycles
Day 1-2× ≥1.36% glu + noct ≥1.36%
glu via auto cycles (Dianeal)
Chow84 (2014) Open-label RCT,
4 mo, public
1 center in HK;
23 ico, 33 glu
Adults; prevalent CAPD;
peritonitis
Prior ico, clinically
unstable
Noct 1× ico + day 2-3× ≥1.36%
glu (Dianeal)
3-4× ≥1.36% glu per 24 h (Dianeal)
Davies 85,103
(2003)
Double-blind RCT,
6 mo, Baxter
Multiple centers in
DE, SE, UK; 28
ico, 22 glu
Adults; prevalent CAPD/
APD; PD: ≥2.27% glu
avg over day; urine >
750 mL/d; H/HA; fluid
overload
<12-mo life
expectancy,
peritonitis, prior ico,
other PD soln
Noct 1× ico (CAPD) or day
1× ico (APD) + BL PD Rx
(fixed) for rest of 24 h (Dianeal)
Noct 1× 2.27% glu (CAPD) or day
1× 2.27% glu (APD) + BL PD Rx
(fixed) for rest of 24 h (Dianeal)
de Moraes86
(2015)
Open-label RCT,
3 mo, Baxter
7 centers in BR;
33 ico, 27 glu
Adults; prevalent APD;
H/HA/LA
Peritonitis; DM; <12-
mo life expectancy;
HIV, cancer
Day 1× ico + noct ≥1.36% glu
(Dianeal) via auto cycles
Day 1× 2.27% glu + noct ≥1.36% glu
via auto cycles (Dianeal)
Finkelstein87,104
(2005)
Double-blind RCT,
2 wk, Baxter
US, AU; 47 ico,
45 glu
Adults; prevalent APD;
H/HA
Peritonitis Day 1× ico + BL PD Rx (fixed)
for rest of 24 h (Dianeal)
Day 1× 3.86% glu + BL PD Rx (fixed)
for rest of 24 h (Dianeal)
Konings88
(2003)
Open-label RCT,
4 mo, Baxter
6 centers in NL,
DE; 22 ico, 18 glu
Prevalent CAPD/APD Peritonitis, type 1 DM,
cancer, CHF/
CAD ≥ NYHA III
Noct 1× ico (CAPD) or day
1× ico (APD) + BL PD Rx
(fixed) for rest of 24 h (Dianeal)
Noct 1× 1.36% glu (CAPD) or day
1× 1.36% glu (APD) + BL PD Rx
(fixed) for rest of 24 h (Dianeal)
Lin89,105 (2009) Double-blind RCT,
4 wk, public
7 centers in CN;
98 ico, 103 glu
Adults; prevalent CAPD;
PD: 2.27% glu long-
dwell, any transporters
Infection; hepatitis,
cancer, cardiac
diseases
Noct 1× ico + day 2-3× 1.36%-
2.27% glu (Dianeal)
Noct 2.27% glu + day 2-3× 1.36%-
2.27% glu (Dianeal)
Mistry90,91,106
(1994)
Open-label RCT,
6 mo, M. L. Labsa
11 centers in UK;
106 ico, 103 glu
Adults; prevalent
CAPD; ≤1× 3.86% glu
Peritonitis Noct 1× ico + day 2-3× ≥1.36%
glu (Dianeal)
Noct 1× ≥1.36% glu + day 2-
3× ≥1.36% glu (Dianeal)
Ota92,107 (2003) Double-blind RCT,
4 wk, Baxter
16 centers in JP;
28 ico, 29 glu
Adults; prevalent CAPD Peritonitis; infection,
hepatitis, cancer
Noct 1× ico + day 3-4× 1.36%-
2.27% glu (Dianeal)
Noct 1× 1.36%-2.27% glu + day 3-
4× 1.36%-2.27% glu (Dianeal)
Paniagua93
(2009)
Open-label RCT,
12 mo,
public + Baxter
4 centers in MX;
30 ico, 29 glu
Adults; prevalent CAPD;
DM; H/HA
Peritonitis, hepatitis,
HIV, cancer
Noct 1× ico + day 3× ≥1.36%
glu (Dianeal)
Noct 1× ≥2.27% glu + day 3× ≥1.36%
glu (Dianeal)
Plum94,108
(2002)
Open-label RCT,
12 wk, Baxter
8 centers in EU;
20 ico, 19 glu
Prevalent APD; PD:
2.27% glu long-dwell
Dry period infection,
peritonitis, hepatitis,
HIV, cancer
Day 1× ico + noct ≥1.36% glu
(Dianeal) via auto cycles
Day 1× 2.27% glu + noct ≥1.36% glu
via auto cycles (Dianeal)
Posthuma95-
97,109 (2000)
Open-label RCT,
1 y, public + M. L.
Labsa
1 center in NL;
19 ico, 19 glu
Adults;
incident + prevalent APD
Peritonitis, <24-mo
life expectancy
Day 1× ico + noct ≥1.36% glu
(Dianeal) via auto cycles
Day 1× ≥1.36% glu + noct ≥1.36%
glu via auto cycles (Dianeal)
Rodríguez-
Carmona98
(2007)
Crossover RCT,
10+10 d, Baxter
1 center in ES;
21
Prevalent APD NR Day 1× ico + noct ≥1.36% glu
& 1.1% amino acid soln
(Dianeal, Nutrineal) via auto
cycles
Day 1× ≥1.36% glu + noct ≥1.36%
glu & 1.1% amino acid soln via auto
cycles (Dianeal, Nutrineal)
(Continued)
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Original Investigationwas assessed to be moderate. The number of patients who
received a kidney transplant was balanced between groups
(Table S9).
Of note, not included in this analysis is that a large
but unquantifiable proportion of patients in the glucose
group of long-term studies underwent an increase in
glucose concentration or icodextrin to obtain increased
UF. This is an explicit finding in almost all of the long-
term studies in the glucose groups, confounding the
comparison with the icodextrin groups.82,83,93,97,99,101
This favors technique survival in the glucose group by
ameliorating UF failure and potentially masks benefit
from icodextrin.
Quality of Life
HRQoL results were obtained from 2 RCTs with 12
months’ duration, 1 with published54 and 1 with un-
published93 data. Results for the SF-36 generic question-
naire (MD for Physical Component Summary score, 0.95
[95% CI, −2.96 to 4.86]; MD for Mental Component
Summary score, 0.33 [95% CI, −7.41 to 8.06]) and the
overall score of disease-specific modules (MD, 0.60 [95%
CI, −4.93 to 6.13]; Fig S3C) were inconclusive. No sub-
group analyses were performed due to the small number
of contributing studies.
Exclusion of the open-label study considered at high
risk of bias for this outcome93 did not change this
conclusion. The certainty of the available evidence for all
HRQoL outcomes is low or very low, mainly due to lack of
blinding and the low number of contributing RCTs.
Peritoneal UF
UF (any measure) was more effective in the icodextrin
than glucose group for up to 6 months, but no
difference between groups was seen in the long-term
(Fig 4A).
Sensitivity analysis excluding studies using neutral-pH
low-GDP glucose dialysate in the control group82,101 did
not change the direction or magnitude of this effect (Fig
S3D). The weighted mean net long-dwell UF in the
glucose group was 261 (short term), 215 (medium term),
and 465 mL (long term). It was higher for icodextrin
versus glucose by 230 to 290 mL for any treatment
duration (Fig S3E). A similar effect was also demonstrable
for UF expressed as mL per day (Fig S3F). The overall
certainty of evidence is high for up to 6 months’ treatment
duration but was downgraded for the long-term subgroup
because of unexplained heterogeneity.
In the subgroup analysis for transport category, the
superiority of icodextrin versus glucose was large in
both high/high-average and low-average transporters,
whereas there was no difference in low transporters
(Figs 4B and S6B). UF was improved with icodextrin
compared with any strength of glucose PD solution (Fig
S7C). Incident and prevalent patients (Fig S4C), as well
as diabetic and nondiabetic patients (Fig S5C), benefited
from icodextrin in terms of UF.835
Figure 2. Review authors' judgments about each risk-of-bias item for (A) objective and (B) subjective outcomes for all 20 included
studies.139
Original InvestigationAdverse Events
Safety outcome results were similar for icodextrin and
glucose, including the number of serious AEs (RR, 0.91
[95% CI, 0.76-1.10]; Fig S3G), total AEs (RR, 1.04
[95% CI, 0.94-1.16]; Fig S3H); AEs leading to with-
drawal (RR, 0.87 [95% CI, 0.65-1.17]; Fig S3I), hos-
pitalizations (RR, 0.81 [95% CI, 0.64-1.04]; Fig S3J),
and peritonitis (RR, 1.08 [95% CI, 0.88-1.32]; Fig S3K).
The certainty of the evidence is moderate to high for
these safety outcomes.
Uncontrolled Fluid Overload
Definitions of this outcome varied. The quoted defini-
tions are “withdrew prior to study completion due toTable 2. Summary of Findings and Certainty of Evidence for Sele
Outcome
No. of Pts
(Studies)
Event Rates or No.
of Pts Relative
Effect (95%
CI)
A
Glucose Icodextrin
E
G
Primary Outcomes
Mortality 1,685
(19 RCTs)
20/805
(2.5%)
12/880
(1.4%)
OR, 0.49
(0.24-1.00)
R
1
PD technique
failure
1,401
(18 RCTs)
20/695
(2.9%)
17/706
(2.4%)
OR, 0.77
(0.39-1.50)
R
1
QoLa 116
(2 RCTs)
48 68 − W
w
Net peritoneal ultrafiltration
≤6 wk 694
(6 RCTs)
358 337 − W
w
3-6 mo 362
(6 RCTs)
181 182 − W
w
1-2 y 104
(3 RCTs)
48 56 −
Secondary Outcomes
SAE 1,303
(11 RCTs)
124/613
(20.2%)
142/690
(20.6%)
RR, 0.91
(0.76-1.10)
R
1
Pts with
peritonitis
1,348
(15 RCTs)
117/631
(18.5%)
152/717
(21.2%)
RR, 1.08
(0.88-1.32)
R
1
Uncontr fluid
overload
602
(8 RCTs)
28/295
(9.5%)
11/307
(3.6%)
RR, 0.43
(0.24-0.76)
R
1
Note: Only absolute values considered.
Abbreviations: CI, confidence interval; GRADE, Grading of Recommendations Asses
Life; MD, mean difference; OR, odds ratio; PD, peritoneal dialysis; pt, patient; QoL, qu
serious adverse event; uncontr, uncontrolled.
aKDQOL disease-specific module.
836uncontrolled fluid overload”82; “shift to [icodextrin]
use in [glucose] group, the reason is reduced UF ca-
pacity with [glucose] solution” (Dr Chen); “UF failure
leading to withdrawal”86; “uncontrolled fluid over-
load”90; “uncontrolled fluid overload” (Dr Paniagua);
“causes for withdrawal: water removal failure” (Dr
Takatori); and “admitted to the hospital due to a
reduced UF.”112
Icodextrin reduced the risk for uncontrolled fluid
overload overall and for the long-term subgroup (Figs 5
and S3L). The control group rate of uncontrolled fluid
overload was 95 per 1,000 patients. Icodextrin led to a risk
difference of 54 fewer per 1,000 (23-72 fewer). Our
confidence in the evidence is high.cted Outcomes GRADE)
nticipated Absolute Effects
Overall Certainty
of Evidence
ffect With
lucose
Difference With
Icodextrin (95% CI)
isk was 25 per
,000
RD, 13 fewer per 1,000
(19 fewer to 0 fewer)
444
Moderate
isk was 29 per
,000
RD, 6 fewer per 1,000
(17 fewer to 14 more)
444
Moderate
eighted mean
as 76.8
MD, 0.6 higher (4.93 lower
to 6.13 higher)
44 Low
eighted mean
as 261 mL
MD, 282.49 higher (238.31
higher to 326.67 higher)
4444 High
eighted mean
as 215 mL
MD, 286.45 higher (75.36
higher to 497.55 higher)
4444 High
Weighted mean
was 465 mL
MD, 237.38 higher (213.1
lower to 687.87 higher)
44 Low
isk was 202 per
,000
RD, 18 fewer per 1,000
(49 fewer to 20 more)
4444 High
isk was 185 per
,000
RD, 15 more per 1,000
(22 fewer to 59 more)
4444 High
isk was 95 per
,000
RD, 54 fewer per 1,000
(72 fewer to 23 fewer)
4444 High
sment, Development and Evaluation; KDQOL, Kidney-Disease Specific Quality of
ality of life; RCT, randomized controlled trial; RD, risk difference; RR, risk ratio; SAE,
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Figure 3. Mortality events; short term after 6 or more weeks, medium term after 3 to 6 months, and long term after 1 to 2 years. Risk
of bias legend: (A) Random sequence generation (selection bias), (B) allocation concealment (selection bias), (C) blinding of par-
ticipants and personnel (performance bias), (D) blinding of outcome assessment (detection bias), (E) incomplete outcome data (attri-
tion bias), (F) selective reporting (reporting bias), and (G) other bias. Abbreviations: CI, confidence interval; GLU, glucose; ICO,
icodextrin.
Original InvestigationGlucose Exposure
Peritoneal membrane glucose exposure was defined as
total amount of glucose infused over 24 hours. Patients
in the icodextrin group were exposed to ~45 g less
daily glucose than those in the glucose group (Fig
S3M), with no observable differences by treatment
duration.AJKD Vol 75 | Iss 6 | June 2020Daily glucose absorption was defined as the
difference between the total amount of glucose admin-
istered over 24 hours minus the amount remaining in
drained effluent. In the icodextrin group, patients
absorbed ~42 g less daily glucose than in the glucose
group (Fig S3N), again with no differences by treatment
duration.837
Figure 4. Ultrafiltration (any measure); (A) by duration of treatment; (B) by transport category including high/high-average (H/HA),
low-average (LA), and low (L) transporters. Risk of bias legend: (A) random sequence generation (selection bias), (B) allocation
concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blinding of outcome assessment
(detection bias), (E) incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), and (G) other bias. Abbrevia-
tions: CI, confidence interval; GLU, glucose; ICO, icodextrin.
Original InvestigationThere was no clear difference in fasting plasma glucose
levels (Fig S3O) between groups. No difference in HbA1c
levels was observed (Fig S3P).
Other Outcomes
There was no difference in kidney function (eg, medium-
term residual urine volume MD, 43.02 [95% CI, −94.73 to
180.77] mL; high certainty; Fig S3Q-R), drained body
weight (eg, medium-term MD, −0.34 [95% CI, −2.54 to
1.86] kg; high certainty; Fig S3S), or inflow pain (eg,
medium-term RR, 1.05 [95% CI, 0.51-2.17]; very low
certainty; Fig S3T) between treatment arms. Icodextrin
improved short-term peritoneal small-molecule clearance
and decreased serum lipid levels, but these effects were not
sustained (Fig S3U-X). Serum sodium concentration was
lower in icodextrin-treated patients (Fig S3Y).838Discussion
In this systematic review, we show that icodextrin resulted
in increased UF, fewer episodes of fluid overload, reduced
daily glucose absorption, and probably decreased mortality
risk. The findings concerning mortality risk are consistent
with observational data.114-122 The review highlights dif-
ferential benefit in high/high-average transport patients, a
subgroup with particularly high mortality risk.34-36 This
finding is again consistent with observational data.123-125
In this review, there is a potential effect modification by
whether the control group received neutral-pH low-GDP
glucose dialysate. Directionally, the omission of the 2
studies82,101 that used these fluids did not change our es-
timates. Of note, the mortality effect is driven by studies
with the most events (ie, those with longer follow-up),AJKD Vol 75 | Iss 6 | June 2020
Figure 4. (Con’d).
Original Investigationwith higher-risk cohorts (eg, Paniagua et al,93 in which
patients all had diabetes and moreover were high or high-
average transporters) or from older eras when mortality
rates were higher (eg, Posthuma et al,95-97 in which patients
were recruited from 1994-1997). Unlike the studies of East
Asian populations82,83,92 and those with relatively healthy
cohorts,85,90 the former studies have generally higher-risk
participants, who are both more sensitive to intervention
and contributing the majority of events to the analysis.
UF was increased in the icodextrin group, but the
benefit was attenuated in long-term studies. This may be
due to the mentioned confounding from higher glucose
concentrations or icodextrin use in the glucose groups in
these trials.82,83,93,97,99,101 There was no benefit to ico-
dextrin in terms of PD technique failure. However, this
outcome is confounded by co-interventions or contami-
nation between groups, as described in the Results section.
In addition, the selection of patients for all clinical trials
(including those in this meta-analysis) results in partici-
pants who are more likely to be treatment adherent and
hence less likely to “fail” on PD. Unsurprisingly, our
findings contrast with those of observational studies,
which generally show improved technique survival with
icodextrin.114-117,120,121,126 There were short-term bene-
fits with icodextrin in terms of small-solute clearance and
serum cholesterol levels. Importantly, none of these
identified benefits were accrued at the cost of greater AEs,
loss of residual kidney function, or peritonitis. Data forAJKD Vol 75 | Iss 6 | June 2020patient-centered outcomes were scarce and evidence was
uncertain; available data suggested no difference in HRQoL
or inflow pain between groups.
Several findings relate broadly to carbohydrate meta-
bolism. First, increased serum oligosaccharide levels are
well known to occur with icodextrin but, as we show, do
not lead to an overall excess of AEs. These icodextrin
metabolites are responsible for the decrease in serum
sodium levels that we identified, which is mainly dilu-
tional in nature; that is, a pseudohyponatremia. Second,
the reduction in daily glucose absorption with icodextrin-
containing PD regimens might be expected to reduce
blood glucose levels.86,127 However, our analysis showed
no difference in HbA1c and fasting plasma glucose levels
between groups. Given results of the IMPENDIA-EDEN
trial,128,129 a single exchange of icodextrin per day
instead of glucose may be clinically insufficient as a
glucose-sparing PD regimen. Alternatively, the effect may
be too small to be demonstrable in our data set, which
includes many nondiabetic patients (a “sub–meta-
analysis” of the effect of icodextrin-containing PD regi-
mens on glycemic control exclusively in diabetic patients
is underway). Third, icodextrin might be expected to
ameliorate the progressive damage to peritoneal mem-
brane structure and function that occurs over time on PD.
Icodextrin reduces daily exposure of the peritoneum to
glucose and contains lower levels of GDPs compared with
conventional glucose solutions130-132 with probably839
Figure 5. Uncontrolled fluid overload. Results with random-effects modeling are: risk ratio (RR; ≤6 weeks, 3.00 [0.13-69.87]; 3-6
months, 0.45 [0.08-2.58];1-2 years, 0.39 [0.21-0.75];total, 0.43 [0.24-0.78]. Risk-of-bias legend: (A) random sequence generation
(selection bias), (B) allocation concealment (selection bias), (C) blinding of participants and personnel (performance bias), (D) blind-
ing of outcome assessment (detection bias), (E) incomplete outcome data (attrition bias), (F) selective reporting (reporting bias), and
(G) other bias. Abbreviations: CI, confidence interval; GLU, glucose; ICO, icodextrin; SD, standard deviation; Std, standardized.
Original Investigationgreater peritoneal biocompatibility.89,133 Despite this, we
showed no sustained difference in peritoneal small-solute
clearance between icodextrin-containing and glucose-
only PD regimens. Again, it may be that a single ex-
change of icodextrin per day instead of glucose is clini-
cally insufficient as a PD regimen with enhanced
biocompatibility. Alternatively, peritoneal clearance may
be too insensitive as a marker of peritoneal membrane
structure; there is evidence that the peritoneal solute
transport rate is better.134
Trial quality varied among included RCTs (Table S5).
The patients analyzed here may not be representative of the
true patient population due to our reliance on published
RCTs, with restrictive selection criteria in some instances.
Only 2 trials reported and analyzed the outcome of dia-
betic patients independently, resulting in inconclusive
subgroup analyses. There were not as many trial results as
desirable for the assessments over the long term. The840results should be interpreted with understanding of the
inherent limitations of included studies.
We did not corroborate our results of mortality analysis
using time-to-event methods on individual patient data,
which is a future priority. In addition, we did not assess
potentially important mechanistic outcomes, including
blood pressure,82,88,89,100 antihypertensive medication
burden,82,85,87,90,93,97 and extracellular fluid
volume.82,85,88,89,93,100,102 The analyses are not adjusted
for multiple comparisons, as per standard operating pro-
cedures for meta-analysis.135
The 3 previous meta-analyses of icodextrin versus
glucose did not always identify the same benefits as ours.
The differences arise from the enriched data used in the
current study (Table 3). To quote Jefferson et al, “Sys-
tematic reviews that use only published data perpetuate
such [reporting] bias and possibly compound the issue
through the credibility afforded by the systematicAJKD Vol 75 | Iss 6 | June 2020
Table 3. Comparison of Previous Systematic Reviews With the
Present Study (Exemplary Outcomes)
Htay
et al40
He
et al41
Qi
et al42
Present
Study
Patients included
Studies 13 9 9 20
Patients randomly
assigned
1,322 578 1,190 1,714
Patient survival
Studies 6 4 19
Patients evaluable 816 735 1,685
PD technique failure
Studies 4 18
Patients evaluable 350 1,401
UF, any measure
Studies 4 2 15
Patients evaluable 102 131 1,120
Peritoneal CLcr
Studies 3 4 5 10
Patients evaluable 237 326 528 922
Peritoneal CLurea
Studies 4 4 10
Patients evaluable 326 508 908
Serum glucose
Studies 4 5
Patients evaluable 266 388
Serum triglycerides
Studies 3 7
Patients evaluable 241 560
Abbreviations: CLcr, creatinine clearance; CLurea, urea clearance; PD, peritoneal
dialysis; UF, ultrafiltration.
Original Investigationreview.”48(p 210) In the current study, the principal in-
vestigators of included studies often provided abstracted or
raw data and were included as authors of this study to
stand fully accountable for the results obtained. Addi-
tionally, we have included CSRs of industry-sponsored
trials containing extensive source data,136 all subjected to
rigorous regulatory review.58 Thus, we were able to assess
a markedly greater number of outcomes than previous
reviews.137
There is an urgent need to improve PD outcomes and
reduce associated costs.138 Icodextrin provides a possible
opportunity of increased survival, with a decrease in
important complications such as fluid overload. Icodextrin
appears in many clinical practice guidelines, although with
variable indications (Table S10). This variability is prob-
ably responsible for markedly different icodextrin uptake
between health jurisdictions (Fig S1). Based on our
updated results, there is likely to be benefit from increased
access to and earlier use of icodextrin for patients in many
parts of the world. A revision of relevant best practice
recommendations is warranted, guided by experts after
due deliberation of evidence and context.
It is unlikely that there will be any further large-scale
RCTs comparing icodextrin and glucose. Future efforts
should focus on health economics and patient-centered
outcomes. Further insights into cost-effectiveness/-utilityAJKD Vol 75 | Iss 6 | June 2020and treatment preferences for icodextrin-based PD solu-
tions would be welcome.
In conclusion, our systematic review demonstrates
substantial clinical benefits for icodextrin based on
high-level evidence and suggests an attributable benefit in
the global PD population from greater and perhaps earlier
access to icodextrin for appropriate patients.Supplementary Material
Supplementary File (PDF)
Item S1: Supplementary methods.
Figure S1: Prevalent PD patients on icodextrin, by country.
Figure S2: Funnel plots for all outcomes with ≥10 included studies.
Figure S3: Forest plots for all outcomes that were meta-analyzed,
and for all sensitivity analyses.
Figure S4: Forest plots for subgroup analysis for incident vs prev-
alent patients.
Figure S5: Forest plots for subgroup analysis for diabetic vs
nondiabetic patients.
Figure S6: Forest plots for subgroup analysis for transport types.
Figure S7: Forest plots for subgroup analysis for glucose
concentration.
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